Skip to Content
Merck

H146

4-Hydroxymephenytoin

≥98% (HPLC)

Synonym(s):

(±)-5-Ethyl-5-(4-hydroxyphenyl)-3-methylhydantoin, (±)-5-Ethyl-5-(4-hydroxyphenyl)-3-methylimididazolidine-2,4-dione

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C12H14N2O3
CAS Number:
61837-65-8
Molecular Weight:
234.25
NACRES:
NA.22
PubChem Substance ID:
57654234
UNSPSC Code:
12352100
MDL number:
MFCD00142316

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

4-Hydroxymephenytoin, ≥98% (HPLC)

InChI key

OQPLORUDZLXXPD-UHFFFAOYSA-N

SMILES string

CCC1(NC(=O)N(C)C1=O)c2ccc(O)cc2

InChI

1S/C12H14N2O3/c1-3-12(8-4-6-9(15)7-5-8)10(16)14(2)11(17)13-12/h4-7,15H,3H2,1-2H3,(H,13,17)

assay

≥98% (HPLC)

solubility

DMSO: >5 mg/mL

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Pharmacological activity investigating:
  • The drug effects on metabolization
  • In vitro cytochrome P450 activity in microsomes

Analyte for electron-capture gas chromatography procedures

General description

CYP2C19 metabolite of mephenytoin.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
047M4717V
110M4625V
110M4708V
087K4618
011K4607

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sonja Krösser et al.
European journal of clinical pharmacology, 62(4), 277-284 (2006-03-10)
The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate
M. Salsali, et al.,
Journal of Pharmacological and Toxicological Methods, 44, 461-465 (2001)
Xiao-Ping Chen et al.
Clinical pharmacology and therapeutics, 73(3), 264-271 (2003-03-07)
This study was designed to define the effect of low-dose aspirin administration on the activity of cytochrome P450 (CYP) in normal human subjects. Aspirin, 50 mg daily, was given for 14 days to 18 nonsmoking healthy male volunteers. A modified
J Caslavska et al.
Journal of chromatography. B, Biomedical applications, 656(1), 219-231 (1994-06-03)
Phenotypes for hydroxylation can be predicted by using mephenytoin and dextromethorphan as substrates, whereas phenotypes for acetylation can be determined with caffeine as probe drug. After single-dose administration of one of these drugs, of two of them simultaneously, or of
Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.
M Bajpai et al.
Drug metabolism and disposition: the biological fate of chemicals, 24(12), 1401-1403 (1996-12-01)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service